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Abstract
Introduction: Evidence from clinical samples and geographically limited population studies suggests that vascular
health, diabetes and apolipoprotein ε4 (APOE) are associated with dementia.
Methods: A population-based sample of 856 individuals aged 71 years or older from all contiguous regions of the
United States received an extensive in-home clinical and neuropsychological assessment in 2001-2003. The relation
of hypertension, diabetes, heart disease, stroke, medication usage, and APOE ε4 to dementia was modelled using
adjusted multivariable logistic regression.
Results: Treated stroke (odds ratio [OR] 3.8, 95% confidence interval [CI] 2.0, 7.2), untreated stroke (OR 3.5, 95% CI
1.7, 7.3), and APOE ε4 (OR 2.8, 95% CI 1.7, 4.5) all increased the odds of dementia. Treated hypertension was
associated with lower odds of dementia (OR 0.5, 95% CI 0.3, 1.0). Diabetes and heart disease were not significantly
associated with dementia. A significant interaction was observed between APOE ε4 and stroke (P = 0.001).
Conclusions: Data from the first dementia study that is representative of the United States population suggest
that stroke, the APOE ε4 allele and their interaction are strongly associated with dementia.
Introduction
Identification of modifiable risk factors for Alzheimer’s
disease (AD), vascular dementia (VaD), and other demen-
tias could potentially lead to a reduction in the human
and economic costs these conditions place on aging
populations. Better prevention of vascular disease and
better treatment of vascular risk factors, in particular,
may hold promise for decreasing the incidence of these
debilitating disorders [1,2]. A number of related vascular
risk factors and conditions – for example, hypertension,
diabetes, heart disease, and stroke – have been studied to
determine their relation to AD and VaD. However, many
of these prior studies have been based on highly selected
clinical samples or community-based samples from geo-
graphically localized areas, thus raising questions about
the generalizability of findings [3].
Studies of blood pressure and prevalent dementia have
noted an inverse relation in late-life [4], perhaps indicating
that the dementia processes itself leads to lower blood
pressure [5]. Incidence studies suggest that midlife hyper-
tension is a risk factor for dementia in late-life, and that
low diastolic and very high systolic pressure in late-life
may also be risk factors [4,5]. Observational studies and
randomized controlled trials provide limited evidence for a
protective effect of antihypertensive therapy [4-9]. How-
ever, bias was introduced to previous trials due to the
large proportion of placebo patients given active treat-
ment, and the number of patients lost to follow-up with
differential drop-out. The impact of hypertension on AD
is controversial and remains to be clarified.
Evidence for the relation between diabetes and
dementia has also been mixed. Studies of the prevalence
of diabetes in those with established dementia have pro-
vided equivocal results [10], perhaps due to methodolo-
gical issues such as survival bias or the effects of AD on
glucose metabolism [11]. Results from incidence studies
have been more consistent, suggesting that dementia is
50 to 100% more likely in individuals with diabetes, and
that the association may be slightly stronger for patients
with VaD than AD [10]. The clinical relevance of possi-
ble underlying pathophysiological mechanisms remains
unclear, although elevated glycosylated hemoglobin
* Correspondence: klanga@umich.edu
4Department of Internal Medicine, University of Michigan, 300 N. Ingalls St.,
Ann Arbor, MI, 48109, USA
Llewellyn et al. Alzheimers Res Ther 2010, 2:19
http://alzres.com/content/2/3/19
© 2010 Llewellyn et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
(HbA1c) levels appear to increase the risk of dementia
[12], and treatments improving glycemic control may
therefore reduce the risk of dementia.
There are conflicting reports on the possible association
between heart disease and dementia. Several studies have
reported a higher risk of dementia or cognitive impairment
in heart disease patients [13-16], whereas other studies
suggest no association [17,18]. Further research is needed
to establish whether these discrepancies reflect methodolo-
gical artifacts, and to clarify the relation between heart dis-
ease and dementia with greater precision.
The prevalence of dementia in people with a history of
stroke is approximately 3.4 to 5.8 times higher than in
those without [19,20], and the incidence of dementia
over 10 to 25 years in those with a history of stroke is
about double that observed in those free of stroke
[13,14]. The presence of cerebrovascular disease and a
temporal relation between cerebrovascular disease and
the onset of dementia are typically central diagnostic cri-
teria for VaD [15-17]. However, cerebrovascular disease
may be identified by neurological examination or brain
imaging rather than a history of clinical stroke, and a
considerable proportion of stroke patients do not develop
dementia or VaD [18]. The association between AD and
stroke remains uncertain due to a lack of conceptual and
taxonomic consensus, although dementia is commonly
associated with concomitant cerebrovascular and AD
pathology in community-based autopsy studies [19].
Genetic predisposition may also modulate the associa-
tion between vascular risk factors, diabetes, and demen-
tia [20]. Apolipoprotein E (APOE) plays a central role in
lipid metabolism, and is the only established genetic risk
factor for late-onset dementia [21]. Some previous stu-
dies suggest that the association between dementia and
hypertension [22], diabetes [23], heart disease [24], or
stroke [25] may be particularly strong among APOE ε4
allele carriers, although other studies suggest an additive
effect with no effect modification [15].
We aimed to assess the relation between vascular
health, diabetes, APOE and dementia using data from the
Aging, Demographics, and Memory Study (ADAMS).
The ADAMS is the first population-based study of
dementia in the USA to include subjects from all regions
of the country, while using a single standardized diagnos-
tic protocol in a population-based sample [3]. The
ADAMS has recently been utilized to estimate the preva-
lence of dementia [16] and cognitive impairment without
dementia [17] in the USA.
Materials and methods
Participants
The ADAMS sample design and selection procedures are
summarized below and described in detail elsewhere [3].
The ADAMS sample was drawn from the larger Health
and Retirement Study (HRS), an ongoing prospective
cohort study of individuals that was designed to investi-
gate the social, health and economic implications of
aging [26]. The HRS began in 1992 and was expanded in
1998 to become a representative sample of all persons in
the contiguous USA older than 50 years of age. Data
were collected from community living and institutiona-
lized adults primarily through telephone interviews, with
an overall response rate of 81% [27]. The ADAMS sam-
ple was derived from a stratified random subsample of
1,770 individuals aged 70 years or older from five cogni-
tive strata based on participants’ cognitive test scores or
proxy-reported cognition from the most recent HRS
interview (in 2000 or 2002). The three highest cognitive
strata were further stratified by age (70 to 79 years vs.
80 years and older) and sex to ensure adequate numbers
in each subgroup. A detailed description of the ADAMS
sample, non-participants and the population weights
used to ensure population representativeness has been
published previously [3]. ADAMS participants did not
differ significantly from nonparticipants in age, sex, or
education, but were more likely to be African-American
(P < 0.05), to have been a self-respondent at the prior
HRS wave (P < 0.05), and to have scored in the normal
range on the HRS cognitive test in the prior wave (P <
0.05) [3]. ADAMS initial assessments were conducted
between July 2001 and December 2003, after a mean per-
iod of 13.3 months (standard deviation (SD) 6.9) from
the last HRS interview. Participants were aged 71 years
or older at the initial ADAMS assessment. A total of 856
individuals (56% of the nondeceased target sample) parti-
cipated in all phases of the dementia assessment (Figure
1) [3].
The institutional review boards at Duke University
Medical Center and the University of Michigan
approved the study procedures, and all study partici-
pants or their surrogates provided informed consent.
Measures
Full details of the ADAMS assessment and diagnostic
procedures are described elsewhere [3]. A nurse and a
Figure 1 Study flow diagram. ADAMS, Aging, Demographics and
Memory Study.
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neuropsychology technician conducted an assessment of
all participants at their residence. The following informa-
tion about the participant was collected from a knowl-
edgeable informant: chronological history of cognitive
symptoms, current neuropsychiatric symptoms, measures
of severity of cognitive and functional impairment, and
family history of memory problems. During the assess-
ment, the participant completed a battery of neuropsy-
chological measures, a measure of depressive symptoms,
a standardized neurological examination, blood pressure
measurements, collection of buccal DNA samples for
APOE genotyping (presence of the ε4 allele), and a
seven-minute videotaped segment covering portions of
the cognitive status and neurological examinations. Med-
ical record releases were also sought to obtain relevant
neuroimaging and laboratory results from participants’
physicians. A consensus expert panel of neurologists,
neuropsychologists, geriatric psychiatrists, and internists
reviewed all information for all participants collected
during the in-home assessment first without and
then with medical records and assigned final diagnoses.
The consensus panel used clinical judgment to assign
the final diagnosis based on currently accepted standar-
dized international criteria for dementia (Diagnostic and
Statistical Manual of Mental Disorders (DSM)-III-R and
DSM-IV) [28,29], AD (National Institute of Neurological
and Communicative Disorders and Stroke - Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA)) [30], and VaD (National Institute of Neurolo-
gical Disorders and Stroke - Association Internationale
pour la Recherché et l’Enseignement en Neurosciences
(NINDS-AIREN)) [31]. The consensus panel also made
an estimate of the year of dementia onset based on the
available cognitive and additional data. Non-demented
participants were also further divided into two categories:
normal cognitive function and cognitive impairment
without dementia (defined as mild cognitive or functional
impairment that did not meet the criteria for dementia,
or performance that was both below expectation and
at least 1.5 SDs below published norms on any neuropsy-
chological test) [17]. It should be noted that the distribu-
tion of diagnoses becomes nationally representative only
after population weights are applied [3].
The presence of hypertension, diabetes, heart disease,
and stroke was established based upon self- or proxy-
report of these conditions at the HRS interview prior to
the ADAMS assessment. During the HRS interview, each
respondent was asked whether a doctor had ever told
them that they had hypertension (’high blood pressure or
hypertension?’), diabetes (’diabetes or high blood sugar?’),
heart disease (’heart attack, coronary heart disease, angina,
congestive heart failure, or other heart problems?’), or a
stroke (’stroke?’). In addition to self-report of hyperten-
sion, blood pressure was directly measured during the
ADAMS assessment and individuals who had systolic
blood pressure of 140 mmhg or above, or diastolic blood
pressure of 90 mmhg or above on two successive measure-
ments were categorized as hypertensive. Linked Medicare
claims data from 1991 were also used to confirm presence
of stroke. The ADAMS subject or informant was asked to
provide a list of all current medications used, and to pro-
vide the bottles for each of these medications for the nurse
to confirm usage. We used these medication data to assign
a ‘treated’ or ‘untreated’ status based on the current use of
one or more relevant medication for each condition
(hypertension, diabetes, heart disease, and stroke).
Statistical analysis
The probability that an individual participated in
ADAMS was modelled using logistic regression as a
function of covariates derived from the HRS, such as
age, sex, education, marital status, HRS cognition scores,
residential status, and health conditions, to develop non-
response adjustments to the sample selection weights.
Population sample weights were then constructed to
take into account the probabilities of selection in the
stratified sample design and to adjust for differential
nonparticipation [3]. Multivariable logistic regression
models were then used to determine the relation of vas-
cular health (hypertension, heart disease and stroke),
diabetes and APOE to all-cause dementia and the com-
mon dementia subtypes (AD and VaD). We adjusted for
age, sex, education, ethnicity, and HRS wave in basic
models, and also corrected for all of the other variables
in fully adjusted models. Adjustment for stroke was not
incorporated in the fully adjusted VaD models and we
did not examine the association between stroke and
VaD because cerebrovascular disease is a central diag-
nostic criterion for VaD [31]. In a series of secondary
analyses we examined the associations between vascular
conditions, diabetes and dementia separately by treat-
ment status and examined interactions with APOE gen-
otype. In a sensitivity analysis we also excluded those
with cognitive impairment without dementia from the
non-demented control group. In a second sensitivity
analysis we restricted conditions to those reported in
the HRS before the estimated onset of dementia in
order to help establish the temporal relation of observed
associations. All analyses were conducted using Stata SE
version 9.2 (StataCorp, College Station, TX, USA).
Results
The characteristics of the ADAMS population are shown
in Table 1. Just over half of the sample was comprised of
women, over half had received at least nine years of educa-
tion, and almost three-quarters were white in ethnic ori-
gin. Over half of the study population had hypertension
and had heart disease, and stroke and diabetes were also
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relatively common. More than one-quarter of the sample
were APOE ε4 carriers. Participants with dementia were
generally older, less educated and with a higher proportion
of women than non-demented controls. The prevalence of
diabetes was lower in the demented group, whereas the
prevalence of stroke and APOE ε4 was higher.
The associations observed between vascular health,
diabetes, APOE and dementia are shown in Table 2. We
first adjusted for age, sex, education, ethnicity and HRS
wave (basic adjusted models), and then added all other
covariates (fully adjusted models). Stroke and APOE ε4
were clearly associated with dementia, and these results
changed little by additional adjustment. Stroke and
APOE ε4 were also associated with increased odds of
AD. There was little suggestion of an association
between hypertension, diabetes or heart disease and AD.
APOE ε4 was also associated with VaD, and the
strength of the association between APOE and the main
dementia subtypes was similar. The associations
between hypertension, diabetes and heart disease and
VaD were not statistically significant.
Table 3 shows the association between untreated and
treated vascular conditions, diabetes and dementia.
Treated hypertension was associated with lower odds of
dementia and lower odds of AD. There was some sug-
gestion that untreated heart disease might increase the
odds of dementia (P = 0.07). Treated and untreated
stroke were associated with higher odds of dementia
and to a lesser extent AD.
There was little suggestion of an interaction between
hypertension, diabetes, or heart disease and APOE ε4 in
fully adjusted models (P > 0.1). However, there was a
significant interaction between stroke and APOE ε4. We
therefore stratified the association between stroke and
dementia by APOE ε4 genotype (Table 4). There was
little difference between the basic and fully adjusted
models. Those with both stroke and the APOE ε4 allele
were approximately 15 times more likely to be
demented.
Excluding participants who were cognitively impaired
without dementia (n = 241) from the non-demented
control group gave the same pattern of results (data not
Table 1 Baseline characteristics of the study population
Variables Non-demented controls
(n = 548)
All-cause dementia
(n = 308)
Alzheimer’s disease
(n = 229)
Vascular dementia
(n = 48)
Mean age (SD), years 78.3 (6.3) 84.5 (6.9) 85.5 (6.7) 84.0 (6.2)
Women, n (%) 288 (59.4) 213 (68.5) 170 (71.5) 28 (62.1)
Education, n (%)
8 years or less 166 (14.8) 125 (33.5) 93 (32.3) 18 (33.8)
9 years or more 382 (85.2) 183 (66.5) 136 (67.7) 30 (66.2)
Ethnic origin, n (%)
White 395 (87.7) 218 (83.4) 162 (82.1) 36 (87.3)
Black 92 (6.9) 67 (12.4) 49 (12.9) 9 (10.5)
Hispanic 61 (5.4) 23 (4.2) 18 (5.0) 3 (2.2)
HRS wave*, n (%)
2000 157 (31.8) 136 (34.4) 98 (34.5) 26 (42.3)
2002 391 (68.2) 172 (65.6) 131 (65.6) 22 (57.7)
Mean MMSE total (SD) 27.0 (4.1) 15.9 (6.4) 15.4 (6.4) 18.7 (5.9)
Hypertension, n (%)
Untreated 98 (14.9) 61 (23.8) 53 (27.0) 5 (24.0)
Treated 308 (58.6) 150 (44.2) 100 (38.8) 32 (56.8)
Diabetes, n (%)
Untreated 14 (2.1) 16 (4.7) 12 (4.2) 1 (1.3)
Treated 109 (17.9) 31 (11.9) 12 (7.2) 9 (12.5)
Heart disease, n (%)
Untreated 36 (6.1) 32 (11.5) 25 (9.9) 3 (18.3)
Treated 144 (22.3) 79 (28.2) 53 (28.2) 18 (31.8)
Stroke, n (%)
Untreated 114 (17.7) 150 (51.6) 98 (46.0) 36 (82.4)
Treated 22 (3.8) 24 (7.6) 13 (5.2) 10 (15.2)
APOE ε4, n (%) 125 (24.4) 110 (38.6) 87 (38.4) 11 (35.7)
Means and percentages are weighted to adjust for the sampling design. *Participants were selected from the 2000 and 2002 waves of the Health and Retirement
Study (HRS).. APOE ε4, apolipoprotein ε4; MMSE, Mini-Mental State Examination (scores range from 0 to 30 where higher scores indicate better cognitive
function); SD, standard deviation.
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shown). The effect sizes increased slightly for all condi-
tions as we were comparing demented participants with
a more selective group, and confidence intervals were
therefore generally increased due to the reduced sample
size. Restricting vascular conditions and diabetes to con-
ditions reported before the estimated onset of dementia
gave a highly similar pattern of results. For example,
stroke was more likely (odds ratio (OR) 4.8, 95% confi-
dence interval (CI) 2.8 to 8.0) and hypertension was less
likely (OR 0.4, 95% CI 0.2 to 0.6) before the onset of
dementia, whereas no association was observed for dia-
betes or heart disease (P > 0.3). The interaction between
stroke and APOE ε4 remained significant (P = 0.018).
Discussion
In this study we investigated the associations between
hypertension, diabetes, heart disease, stroke, APOE ε4
and dementia. Stroke and the APOE ε4 allele emerged
as being strongly associated with dementia in the USA
population. Treated hypertension was associated with
decreased odds of dementia, whereas untreated heart
disease emerged as being possibly associated. Treated or
untreated diabetes did not appear to increase the odds
of dementia. There was little evidence for an interaction
between APOE ε4 and hypertension, diabetes or heart
disease. However, APOE ε4 did modify the relation
between stroke and dementia as those with stroke who
were APOE ε4 negative had two times higher odds of
dementia, while those with stroke who were APOE ε4
positive had 15 times higher odds of dementia.
Many prior studies of dementia have been based on
highly selected clinical samples or community-based
samples from geographically localized areas [3]. This
analysis is the first to our knowledge to examine the
Table 2 Logistic regression models illustrating the odds of all-cause dementia, Alzheimer’s disease and vascular
dementia (95% confidence intervals) by vascular conditions, diabetes and APOE genotype
All-cause dementia Alzheimer’s disease Vascular dementia
Basic adjusted
models*
Fully adjusted
models†
Basic adjusted
models*
Fully adjusted
models†
Basic adjusted
models*
Fully adjusted
models‡
Hypertension 0.7 (0.4-1.2) 0.7 (0.4-1.2) 0.6 (0.4-1.1) 0.7 (0.4-1.2) 1.7 (0.6-5.0) 2.0 (0.6-6.3)
Diabetes 0.9 (0.5-1.7) 1.1 (0.5-2.1) 0.6 (0.3-1.6) 0.7 (0.3-1.7) 0.8 (0.4-1.4) 0.5 (0.2-1.1)
Heart
disease
1.5 (0.9-2.6) 1.4 (0.8-2.4) 1.4 (0.8-2.6) 1.5 (0.8-2.9) 2.2 (0.7-7.6) 2.6 (0.8-8.4)
Stroke 3.7 (2.2-6.2) 3.7 (2.0-6.9) 2.4 (1.5-3.9) 2.3 (1.3-4.0) § §
APOE ε4 2.5 (1.7-3.9) 2.8 (1.7-4.5) 2.6 (1.5-4.6) 2.6 (1.5-4.8) 2.3 (1.0-5.2) 2.3 (1.1-5.1)
Population weights are used to adjust for the sampling design. *Adjusted for age, sex, education, ethnicity, and Health and Retirement Study (HRS) wave.
†Adjusted for age, sex, education, ethnicity, HRS wave, and all other variables in the table. ‡Adjusted for age, sex, education, ethnicity, HRS wave, and all other
variables in the table excluding stroke. §Not examined as stroke is a central diagnostic criterion for vascular dementia [31]. APOE ε4, apolipoprotein ε4.
Table 3 Logistic regression models illustrating the odds of all-cause dementia, Alzheimer’s disease and vascular
dementia (95% confidence intervals) by untreated and treated vascular conditions and diabetes
All-cause dementia Alzheimer’s disease Vascular dementia
Basic adjusted
models*
Fully adjusted
models†
Basic adjusted
models*
Fully adjusted
models†
Basic adjusted
models*
Fully adjusted
models‡
Hypertension
Untreated 1.3 (0.6-2.9) 1.3 (0.6-3.0) 1.4 (0.7-2.8) 1.5 (0.7-3.1) 2.6 (0.5-14.3) 2.9 (0.4-19.9)
Treated 0.6 (0.3-1.0) 0.5 (0.3-1.0) 0.4 (0.2-0.8) 0.5 (0.2-1.0) 1.4 (0.5-4.5) 1.7 (0.5-5.3)
Diabetes
Untreated 2.5 (0.7-8.1) 2.3 (0.7-7.2) 2.1 (0.6-7.0) 2.1 (0.6-6.8) 0.8 (0.1-8.6) (Insufficient cases
observed)
Treated 0.7 (0.4-1.5) 0.9 (0.5-1.8) 0.4 (0.1-1.5) 0.5 (0.1-1.6) 0.8 (0.4-1.4) 0.6 (0.3-1.2)
Heart disease
Untreated 2.1 (1.4-3.3) 1.8 (1.0-3.3) 1.7 (0.8-3.7) 1.6 (0.5-4.6) 4.2 (0.8-20.8) 4.1 (0.9-18.8)
Treated 1.3 (0.7-2.5) 1.2 (0.6-2.4) 1.3 (0.6-2.8) 1.5 (0.7-3.1) 1.8 (0.6-5.5) 2.1 (0.7-6.6)
Stroke
Untreated 3.8 (2.2-6.6) 3.8 (2.0-7.2) 2.6 (1.6-4.2) 2.4 (1.3-4.2) § §
Treated 3.2 (1.6-6.4) 3.5 (1.7-7.3) 1.8 (0.9-3.7) 1.9 (0.8-4.2) § §
Population weights are used to adjust for the sampling design. ‘Untreated’ and ‘Treated’ categories were defined on the basis of a nurse inspection of medicine
bottles currently used. *Adjusted for age, sex, education, ethnicity, and Health and Retirement Study (HRS) wave. †Adjusted for age, sex, education, ethnicity, HRS
wave, apolipoprotein ε4 (APOE ε4) status, and all other variables in the table. ‡Adjusted for age, sex, education, ethnicity, HRS wave, APOE ε4 status, and all other
variables in the table excluding stroke. §Not examined as stroke is a central diagnostic criterion for vascular dementia [31].
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relation between vascular conditions, diabetes and
dementia in a large heterogeneous population-based
sample that is representative of the contiguous USA.
We incorporated an extensive in-home clinical and neu-
ropsychological assessment to determine a consensus
dementia diagnosis using a single standardized diagnos-
tic protocol for all participants, and adjusted for a range
of potential confounders.
A number of possible sources of bias should also be
discussed. A proportion of the HRS sample died or were
lost to follow-up before they could be assessed in the
ADAMS. The response rate for the ADAMS study was
also moderate (56% of the nondeceased target sample),
which could pose a threat to the representativeness of
the study. However, extensive information about indivi-
duals who refused to participate was available from the
parent HRS, including level of cognitive function, which
was incorporated in the population weights used to
ensure the representativeness of the ADAMS sample. As
we studied the relation between vascular conditions, dia-
betes and dementia cross-sectionally, bias could never-
theless have occurred due to survival effects. The
association with the conditions would have been inflated
if mortality in those with vascular conditions or diabetes
was lower in those that were also demented. More
likely, the combination of vascular conditions, diabetes
and dementia may have led to increased mortality and
an underestimation of the relation. However, the same
pattern of results was observed when we restricted our
analyses to conditions reported before the estimated
onset of dementia. Although dementia was diagnosed by
generally accepted international criteria and a central
consensus committee, the possibility of misdiagnosis
must be noted, particularly when distinguishing between
Alzheimer’s disease, vascular dementia and other
dementias.
Although previous studies provide equivocal evidence
to suggest that antihypertensives may be neuroprotective
[4-9], the prevalence of dementia and AD was lower in
treated hypertensives than untreated hypertensives in
the present study. Thus the importance of hypertension
may be underestimated if studies fail to account for
antihypertensive treatment. Our results add to the
inconsistent literature to suggest that diabetes [10] and
heart disease [32-37] may have a limited association
with dementia on a population level. Our findings are
consistent with previous studies suggesting a three to
six times higher prevalence of dementia in stroke
patients [19,20]. Interestingly, the prevalence of stroke
was higher in participants with AD, and the association
between stroke and dementia was not limited to all-
cause dementia or VaD. Our results are also in line with
studies demonstrating that APOE ε4 is an important
risk factor for dementia [21].
Hypertension is a risk factor for stroke, ischemic white
matter lesions, silent infarcts, and general atherosclerosis,
and has also been related to AD pathology [5]. Dementia
is commonly associated with concomitant cerebrovascular
and AD pathology in community-based autopsy studies
[19]. Possible mechanisms linking stroke and dementia
include vascular lesions, white-matter changes, or combi-
nations of these and AD pathology [18]. APOE ε4 is asso-
ciated with hippocampal, amygdala, and entorhinal cortex
atrophy, increased brain atrophy, increased white matter
hyperintensity volumes and altered cerebral blood flow
and glucose metabolism [38], however the mechanisms for
these changes remain unclear. Although some studies sug-
gest that the association between vascular conditions and
dementia may be modified by APOE ε4 [22-25], we only
observed a significant interaction with stroke. Based on
these findings, we postulate that stroke and APOE may
lead to dementia via related mechanisms.
Conclusions
Data from the first dementia study that is representative
of the USA population suggest that antihypertensive
medications may be neuroprotective, whereas stroke and
APOE ε4 are strongly associated with dementia. It
remains to be established which pathological mechan-
isms are clinically important on a population level,
although our evolving understanding of the etiology of
dementia has the potential to inform more effective
interventions and treatments. Interventions designed to
reduce the incidence of stroke may also be effective in
reducing the incidence of dementia, particularly in
APOE ε4 carriers.
Table 4 Logistic regression model illustrating the odds of all-cause dementia (95% confidence intervals) by
combinations of stroke and APOE genotype
n Basic adjusted models* Fully adjusted models†
Stroke - APOE ε4 - 388 Reference Reference
Stroke + APOE ε4 - 219 2.2 (1.2-4.0) 2.2 (1.1-4.2)
Stroke - APOE ε4 + 151 1.4 (0.8-2.4) 1.3 (0.7-2.5)
Stroke + APOE ε4 + 84 14.8 (6.3-34.9) 14.9 (5.8-38.0)
P for stroke × APOE ε4 interaction = 0.001†
Population weights are used to adjust for the sampling design. *Adjusted for age, sex, education, ethnicity, and Health and Retirement Study (HRS) wave.
†Adjusted for age, sex, education, ethnicity, HRS wave, heart disease, hypertension, and diabetes. APOE ε4, apolipoprotein ε4.
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